膳食纤维作为益生元对泰国肥胖儿童肠道微生物群的影响
研究概览
详细说明
全球儿童肥胖的患病率正在上升。 40 年来,儿童和青少年超重和肥胖的患病率从 4% 急剧上升到 18%。
肥胖的原因是基因-环境相互作用。 最近的证据表明,肠道微生物群参与能量调节和炎症。世界卫生组织对儿童和青少年肥胖的定义是 BMI 等于或高于同年龄和性别的中位数 +2 标准差 (SD)( WHO)参考 儿童肥胖管理是通过改变饮食习惯和身体活动水平改变治疗性生活方式。 益生元的消耗是肠道微生物利用的不可消化的多糖,然后微生物会响应双歧杆菌中益生元摄入量的变化而发生变化,并导致体重减轻和肥胖。 微生物代谢物短链脂肪酸 (SCFA) 可能对宿主生理学的各个方面产生影响,然后可能会降低体重和肥胖。
肥胖的炎症机制,来源于革兰氏阴性菌细胞外膜的脂多糖(LPS)是炎症的触发因素。 IL-1β。 循环 LPS 水平与脂肪细胞中 TNF-α 和 IL-6 浓度升高有关。
菊粉型果聚糖是不易消化、完全可溶且可发酵的食品成分,具有已知的益生元特性,天然存在于菊苣根和菊芋(一种生长于泰国的植物)中,它们在结肠中发酵产生 SCFA。 通过增加促进健康的细菌数量和减少潜在有害物种的数量,优先刺激双歧杆菌生长。
关于益生元对超重或肥胖儿童肠道菌群组成的影响,只有一项研究。 该研究进行了一项随机对照试验,以研究 7-12 岁超重或肥胖的儿童。 参与者被随机分配到每天一次服用富含低聚果糖的菊粉(OI;8 克/天;n = 22)或麦芽糖糊精安慰剂(等热量剂量,对照组;n = 20)的组,持续 16 周。 在基线和 16 周时收集粪便样本,并通过 16S 核糖体核糖核酸 (rRNA) 测序和 qPCR 分析微生物群的组成。 主要结果是体脂百分比从基线到 16 周的变化。 16 周后,定量聚合酶链反应 (qPCR) 显示双歧杆菌属显着增加。 OI 组与对照组相比。 16S rRNA 测序显示,食用 OI 的组中双歧杆菌属物种显着增加,普通拟杆菌减少。食用 OI 的儿童体重 z 值显着降低(降低 3.1%),体脂百分比(降低2.4%)、躯干脂肪百分比(下降 3.8%)、白细胞介素 6 与基线相比(下降 15%)与服用安慰剂的儿童相比。
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Bangkok、泰国、10330
- Chulalongkorn University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 7 至 15 岁的儿童
- 体重指数 (BMI) ≥ 中位数 + 2 标准差 (SD)
排除标准:
- 综合征性肥胖和单基因肥胖的基础疾病
- 肥胖的内分泌原因(例如 甲状腺功能减退症,生长激素缺乏症)
- 使用影响食欲或体重的药物(例如 皮质类固醇)
- 参加其他同时进行的减肥计划
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:原素
A组消耗了我们的专利技术从泰国耶路撒冷朝鲜蓟中提取的10克菊粉(专利编号。
15858)每天晚餐前一次管理一次。
|
干预组(A组)消耗了我们的专利技术从泰国耶路撒冷朝鲜蓟中提取的10克菊粉(专利编号。
15858)每天晚餐前一次管理一次。
安慰剂组(B组)接受了等量水平的麦芽糊精,而饮食纤维建议小组(C组)根据适合年龄的摄入建议获得了指导。
其他名称:
|
|
安慰剂比较:麦芽糊精
B组接收了等归化麦芽糊精。
|
干预组(A组)消耗了我们的专利技术从泰国耶路撒冷朝鲜蓟中提取的10克菊粉(专利编号。
15858)每天晚餐前一次管理一次。
安慰剂组(B组)接受了等量水平的麦芽糊精,而饮食纤维建议小组(C组)根据适合年龄的摄入建议获得了指导。
其他名称:
|
|
有源比较器:饮食纤维
C组将获得饮食纤维建议,旨在匹配适合年龄的摄入量建议。
|
干预组(A组)消耗了我们的专利技术从泰国耶路撒冷朝鲜蓟中提取的10克菊粉(专利编号。
15858)每天晚餐前一次管理一次。
安慰剂组(B组)接受了等量水平的麦芽糊精,而饮食纤维建议小组(C组)根据适合年龄的摄入建议获得了指导。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Abundance (Z-score) of Bifidobacterium at Baseline and Month 6
大体时间:Baseline and Month 6
|
The relative abundance of Bifidobacterium was determined using 16S rRNA gene sequencing from stool samples.
The abundance values were then transformed into z-scores based on the distribution of the entire study population at baseline.
A z-score of 0 represents the mean abundance of the population, while positive or negative values indicate the number of standard deviations above or below the mean, respectively.
|
Baseline and Month 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Fat Mass Index (FMI) and Fat-Free Mass Index (FFMI) at 6 Months
大体时间:From the enrollment to the end of intervention at 6 months.
|
Evaluation of body composition changes focusing on Fat Mass Index (FMI) and Fat-Free Mass Index (FFMI).
FMI and FFMI were calculated as the weight of fat mass or fat-free mass in kilograms divided by the square of height in meters (kg/m^2).
Values reported represent the change from baseline to 6 months.
A positive change value indicates an increase in the respective mass index from baseline, while a negative value indicates a decrease.
FFMI measures the amount of fat-free mass (including muscle) relative to height.
|
From the enrollment to the end of intervention at 6 months.
|
|
Change From Baseline in Children's Eating Behaviors and at 6 Months
大体时间:From the enrollment to the end of intervention at 6 months.
|
Change from baseline in Emotional Undereating (EUE) scores at 6 months.
EUE is a subscale of the Children's Eating Behavior Questionnaire (CEBQ), consisting of items scored on a 5-point Likert scale (1 = Never, 5 = Always).
The score for this subscale is calculated as the mean of its constituent items.
|
From the enrollment to the end of intervention at 6 months.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Interleukin-15 at 6 Months (Inulin Group)
大体时间:From enrollment to the end of intervention at 6 months.
|
Mean change in serum Interleukin-15 (IL-15) concentration from baseline to 6 months.
IL-15 was quantified using ELISA as part of an exploratory mechanistic analysis to investigate the gut-muscle axis.
For this specific exploratory assessment, data were analyzed for the inulin group to evaluate within-group changes.
|
From enrollment to the end of intervention at 6 months.
|
|
Change From Baseline in Creatinine/Cystatin C Ratio at 6 Months (Inulin Group)
大体时间:From enrollment to the end of intervention at 6 months.
|
This mechanistic exploratory analysis primarily focused on the inulin intervention group.
A small subset of participants from the placebo and dietary fiber groups (n=5 per group) was included for internal comparison.
Summary statistics are reported for the inulin group.
|
From enrollment to the end of intervention at 6 months.
|
|
Change From Baseline in Amino Acids and Biogenic Amines at 6 Months
大体时间:From the enrollment to the end of intervention at 6 months
|
Variable Importance in Projection (VIP) scores were derived from Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) to assess the contribution of each metabolite to group separation.
VIP scores are continuous, non-negative values with a theoretical minimum of 0. There is no theoretical maximum or fixed upper limit for a VIP score.
A value greater than 1.0 is a universally accepted threshold indicating that a metabolite contributes significantly to the model's projection.
For this analysis, VIP scores are reported as single, group-level cumulative metrics derived directly from the overall multivariate OPLS-DA model.
Because these are model-derived descriptive values reflecting whole-group patterns rather than participant-level summary statistics, individual-level variance does not exist, and standard deviations are not applicable.
|
From the enrollment to the end of intervention at 6 months
|
|
Change From Baseline in Body Mass Index (BMI) Z-score at 6 Months
大体时间:From the enrollment to the end of intervention at 6 months.
|
Change in BMI Z-score from baseline to 6 months.
BMI Z-score (standard deviation score) was calculated based on age and sex using the WHO child growth standards.
|
From the enrollment to the end of intervention at 6 months.
|
|
Change From Baseline in Inflammatory Cytokines (IL-1β, TNF-α and IL-6) at 6 Months
大体时间:From the enrollment to the end of intervention at 6 months.
|
Changes in serum concentrations of Interleukin-1 beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-6 (IL-6) from baseline to 6 months, measured using ELISA.
These markers were assessed to evaluate the effect of the intervention on systemic inflammation.
|
From the enrollment to the end of intervention at 6 months.
|
|
Serum Peptide YY (PYY) at Baseline and 6 Months
大体时间:Baseline and Month 6
|
Serum concentrations of Peptide YY (PYY) measured at baseline and at the end of the 6-month intervention using ELISA.
The data are reported as the mean and standard deviation for each time point to evaluate the response of this appetite-regulating hormone to the intervention.
|
Baseline and Month 6
|
|
Serum Glucagon-like Peptide-1 (GLP-1) at Baseline and 6 Months
大体时间:Baseline and Month 6
|
Serum concentrations of Glucagon-like peptide-1 (GLP-1) measured at baseline and at the end of the 6-month intervention using ELISA.
The data are reported as the mean and standard deviation for each time point to assess changes in this satiety-related hormone.
|
Baseline and Month 6
|
|
Gut Microbiome Enterotype Classification at 6 Months
大体时间:At 6 months
|
Distribution of gut microbiota enterotypes (e.g., Bacteroides vs. Prevotella) among participants at 6 months, determined by clustering analysis of 16S rRNA sequencing data.
|
At 6 months
|
合作者和调查者
调查人员
- 首席研究员:Chonnikant Visuthranukul, M.D.、Chulalongkorn University
出版物和有用的链接
一般刊物
- Visuthranukul C, Sriswasdi S, Tepaamorndech S, Chamni S, Leelahavanichkul A, Joyjinda Y, Aksornkitti V, Chomtho S. Enhancing gut microbiota and microbial function with inulin supplementation in children with obesity. Int J Obes (Lond). 2024 Dec;48(12):1696-1704. doi: 10.1038/s41366-024-01590-8. Epub 2024 Jul 20.
- Panichsillaphakit E, Visuthranukul C, Chongpison Y, Chuaypen N, Kwanbunbumpen T, Uaariyapanichkul J, Chomtho S. The effects of inulin supplementation on eating behaviours in children and adolescents with obesity: a randomized double-blinded placebo-controlled study. Nutr Metab (Lond). 2025 Aug 12;22(1):97. doi: 10.1186/s12986-025-00995-0.
- Visuthranukul C, Leelahavanichkul A, Tepaamorndech S, Chamni S, Mekangkul E, Chomtho S. Inulin supplementation exhibits increased muscle mass via gut-muscle axis in children with obesity: double evidence from clinical and in vitro studies. Sci Rep. 2024 May 16;14(1):11181. doi: 10.1038/s41598-024-61781-1.
- Visuthranukul C, Sriswasdi S, Tepaamorndech S, Joyjinda Y, Saengpanit P, Kwanbunbumpen T, Panichsillaphakit E, Uaariyapanichkul J, Chomtho S. Association of Human Intestinal Microbiota with Lifestyle Activity, Adiposity, and Metabolic Profiles in Thai Children with Obesity. J Nutr Metab. 2022 May 20;2022:3029582. doi: 10.1155/2022/3029582. eCollection 2022.
- Visuthranukul C, Chamni S, Kwanbunbumpen T, Saengpanit P, Chongpison Y, Tepaamorndech S, Panichsillaphakit E, Uaariyapanichkul J, Nonpat N, Chomtho S. Effects of inulin supplementation on body composition and metabolic outcomes in children with obesity. Sci Rep. 2022 Jul 29;12(1):13014. doi: 10.1038/s41598-022-17220-0.
- Panichsillaphakit E, Chongpison Y, Saengpanit P, Kwanbunbumpen T, Uaariyapanichkul J, Chomtho S, Pancharoen C, Visuthranukul C. Children's Eating Behavior Questionnaire Correlated with Body Compositions of Thai Children and Adolescents with Obesity: A Pilot Study. J Nutr Metab. 2021 Jan 15;2021:6496134. doi: 10.1155/2021/6496134. eCollection 2021.
- Saengpanit P, Chomtho S, Sriswasdi S, Rodpan A, Joyjinda Y, Panichsillaphakit E, Uaariyapanichkul J, Tempark T, Bongsebandhu-phubhakdi C, Suteerojntrakool O, Visuthranukul C. Dietary fiber intake and its relationships with lipid profiles and gut microbiota in obese Thai children: a pilot study. J Med Assoc Thai . 2019;102:1282-8.
- Andriyas T, Sriswasdi S, Tansawat R, Uaariyapanichkul J, Chomtho S, Visuthranukul C. Inulin supplementation modulates gut microbiota derived metabolites related to brain function in children with obesity. Sci Rep. 2025 Oct 7;15(1):34843. doi: 10.1038/s41598-025-21079-2.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 639/2017
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.